NEW YORK – Thermo Fisher Scientific said on Thursday that it has signed a partnership agreement with the Terasaki Innovation Center for discovering and developing new diagnostic tools to manage transplant patients.
Under the agreement, Thermo Fisher will have first rights to new technologies developed by TIC for transplant medicine. Financial and other terms of the deal were not disclosed.
TIC, a new organization, is named after transplant pioneer Paul Terasaki, the founder of transplant diagnostics firm One Lambda, which Thermo Fisher acquired in 2012. The center aims to better understand the mechanism of allograft rejection.
The agreement "demonstrates our continued commitment to research and innovation to provide new solutions that address the challenges of today and the future," Nicole Brockway, president of Thermo Fisher's transplant diagnostics business, said in a statement.
"I am excited about our partnership with Thermo Fisher Scientific and One Lambda, the company my father started," said Mark Terasaki, TIC's chairman and an associate professor at the University of Connecticut. "As the global leader in transplant diagnostics, they will play a key role in helping TIC move the legacy of my father forward."
Thermo Fisher's transplant diagnostics product menu includes a number of antibody detection assays, post-transplant monitoring solutions such as its Molecular Microscope Diagnostic System, as well as HLA typing products and lab instrumentation plus software.